Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients

NCT07026279 is registered in ClinicalTrials.gov with Amplia Therapeutics Limited as lead sponsor.

NCT NCT07026279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07026279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients
Lead sponsor
Amplia Therapeutics Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 18, 2025
Completion date
July 31, 2029
Enrollment
67 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer metastatic